Article Text

PDF
FRI0522 The part of function (health assessment questionnaire) in the sf-6d and eq-5d utility measures varies over time in early arthritis (espoir cohort): questionable validity of deriving quality adjusted life years from haq
  1. C. Gaujoux-Viala1,2,3,
  2. A.-C. Rat1,4,
  3. K. Hosseini1,4,
  4. R.-M. Flipo5,
  5. F. Guillemin1,4,
  6. B. Fautrel3
  1. 1Lorraine University, Paris Descartes University, EA 4360 Apemac, Nancy
  2. 2Montpellier I University, Rheumatology, CHU de Nîmes Carémeau, Nîmes
  3. 3Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris
  4. 4INSERM, CIC-EC CIE6, Nancy
  5. 5Rheumatology, Lille University 2, Lille, France

Abstract

Background There is growing emphasis on the cost-effectiveness of treating early arthritis (EA). As few studies directly record the utility measures needed for economic analyses, mapping is often used. Health Assessment Questionnaire (HAQ) is ‘converted’ into utility using regression. The use of such transformed data by regulatory bodies which determine drug availability raises concern as it involves mathematical transformation between measures which may not be clinically equivalent and with potentially variable interrelationships over time.

Objectives We aimed 1) To assess characteristics associated with SF-6D and EQ-5D utility measures in EA 2) To check whether these associations are stable over 3 years.

Methods - Patients: included in the French nationwide cohort of EA ESPOIR (at least 2 swollen joints for less than 6 months and suspicion of RA).

-Data available: SF-6D and EQ-5D utility measures were longitudinally assessed in 813 patients with EA (at baseline, 6 months, 1, 2 and 3 years). Bio-clinical variables and X-rays were also recorded.

-Analysis: The determinants of SF-6D and EQ-5D utility measures at each time-point were assessed by multivariate linear regressions in 618 EA patients followed over 3 years.

Results At baseline, SF-6D was essentially determined by function, HAQ explaining 50.2% of the variance, whereas after 6 months, SF-6D was essentially determined by mental status (55.8 to 57.6% of the variance) and the HAQ represented only 7.3 to 13.2%. At each time-point, EQ-5D was essentially determined by function, HAQ explaining 36.9 to 44.2% of the variance, except at 1 year, it was essentially determined by mental status, explaining 40.8% of the variance and the HAQ only 11% (figure).

Conclusions The major impact of functional ability and mental status, and the variability of the utility determinants over time have consequences for the utility evaluation in EA patients. Evaluation of treatment cost-utility should not be based on utility data transformed from HAQ.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.